Cargando…
Overcoming obstacles to repurposing for neurodegenerative disease
Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer’s Drug Discovery Foundation (ADDF) and the Micha...
Autores principales: | Shineman, Diana W, Alam, John, Anderson, Margaret, Black, Sandra E, Carman, Aaron J, Cummings, Jeffrey L, Dacks, Penny A, Dudley, Joel T, Frail, Donald E, Green, Allan, Lane, Rachel F, Lappin, Debra, Simuni, Tanya, Stefanacci, Richard G, Sherer, Todd, Fillit, Howard M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184781/ https://www.ncbi.nlm.nih.gov/pubmed/25356422 http://dx.doi.org/10.1002/acn3.76 |
Ejemplares similares
-
Advancing Health Systems and Pharmaceutical Relations: Best Practices for Population Health
por: Stefanacci, Richard G., et al.
Publicado: (2018) -
Medicine quality in high-income countries: The obstacles to
comparative prevalence studies
por: Naughton, Bernard David, et al.
Publicado: (2021) -
Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
por: Shineman, Diana W, et al.
Publicado: (2013) -
Phylotocol: Promoting Transparency and Overcoming Bias in Phylogenetics
por: DeBiasse, Melissa B, et al.
Publicado: (2019) -
Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery
por: Lane, Rachel F, et al.
Publicado: (2013)